

Email: ken.latta@nhs.net

Hambleton, Richmondshire and Whitby
Clinical Commissioning Group
Civic Centre, Stonecross
Northallerton
DL6 2UU

Reference

Tel: 01609 767600

Fax: 01609 767601

Website: www.hambletonrichmondshireandwhitbyccg.nhs.uk

Date: 12th May 2014

To: All GP Practice prescribing Leads

Re: **Domperidone MHRA Safety alert: risk of cardiac side effect – restricted indication, new contraindications, reduced dose and duration of use**

Dear Colleague

An MHRA report following a Europe wide review of domperidone safety data identifies this drug to be associated with a small increased risk of serious cardiac side effects. A higher risk was observed in patients older than 60 years, adults taking daily oral doses of more than 30mg, and those taking QT-prolonging medicines or CYP3A4 inhibitors concomitantly. The MHRA advice can be accessed at: <https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=102155>

Indication

- Domperidone is now restricted to use in the relief of symptoms of nausea and vomiting
- It should be used at the lowest effective dose for the shortest possible time.

Contraindications

- Domperidone is contraindicated in people:
 - with conditions where the cardiac conduction is, or could be, impaired
 - with underlying cardiac diseases such as congestive heart failure
 - receiving other medications known to prolong QT or potent CYP3A4 inhibitors – see BNF, manufacturer's SPC and <http://crediblemeds.org/everyone/composite-list-all-qt drugs/>
 - with severe hepatic impairment.
- Patients with these conditions should have their treatment reviewed at their next routine appointment and be switched to an alternative treatment if required.

Posology

Oral formulations:

- For adults and adolescents over 12 years old and weighing 35kg or more, the recommended maximum dose in 24 hours is 30mg (dose interval: 10mg up to three times a day)
- In children under 12 years old and weighing less than 35kg, the recommended maximum dose in 24 hours is 0.75mg/kg body weight (dose interval: 0.25mg/kg body weight up to three times a day)

Suppository formulation:

- Suppositories should only be used in adults and adolescents weighing 35kg or more; the recommended maximum daily dose in 24 hours is 60mg (dose interval: 30mg twice a day)

Duration of treatment

- The maximum treatment duration should not exceed one week
- Patients currently receiving long-term treatment with domperidone should be reassessed at a routine appointment to advise on treatment continuation, dose change, or cessation.



Our Regional Drug and Therapeutics Centre Medicines Information Department included this topic in its May'14 Prescribing Support newsletter http://rdtc.nhs.uk/sites/default/files/may_2014_v1.pdf and provided the following general advice, which GPs may find useful when acting on this safety alert:

Domperidone is one of only two prokinetic drugs available on the UK market, along with metoclopramide. However, similar restrictions were placed on metoclopramide last year by the MHRA. UKMi issued a memo in response to those restrictions (attached for your records). The following advice (adapted from that memo) would appear to be the most pragmatic approach:

- All patients receiving long-term domperidone should have their therapy reviewed.
- A trial of withdrawal of domperidone therapy should be tried in all patients, with full patient engagement.
- For GORD or dyspepsia, ensure all other therapeutic and lifestyle options are optimised. Options are limited. If nausea or vomiting is the predominant symptom, an antiemetic agent could be tried. Appropriate guidelines on management should be followed, such as those from NICE CKS:
 - [Dyspepsia with proven GORD](#) (link)
 - [Dyspepsia of unknown cause](#) (link)
- For gastroparesis, ensure any iatrogenic cause is identified. Assess and correct nutritional state and, in patients with diabetes, check glycaemic control.
 - Short-term low-dose erythromycin (250-500mg tds for up to four weeks) may also be an option (unlicensed), although consultation with local microbiologists is advised.
 - An antiemetic agent may be used to control any symptomatic nausea and vomiting.

I will also contacted South Tees Gastroenterology Department to see if they have any further advice for patients where adequate symptom control cannot be achieved. I will forward any relevant information when I receive it.

If you have any further queries in the interim then do not hesitate to contact me.

Yours sincerely

Ken Latta
Strategic Lead Pharmacist
NYH CSU, Medicines Management Team
